cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combined use of BMN673 and BYL719 may serve as a promising therapeutic strategy for patients with cervical cancer exhibiting aberrant PI3K activation.
|
31545455 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
As reported before, aberrant expression of proteins associated with signaling pathways, such as phosphatidylinositol 3-kinase(PI3K), EGF-R, β-catenin, and Erk and Bcl-2 was discovered in CC.
|
30552693 |
2019 |
cervical cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ARHGAP17 suppresses tumor progression and up-regulates P21 and P27 expression via inhibiting PI3K/AKT signaling pathway in cervical cancer.
|
30641218 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
|
31295843 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the effect of miR-99b-5p (miR-99b) on invasion and migration in cervical cancer through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway.
|
30480801 |
2019 |
cervical cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these findings indicated that OST could be used as a potential sensitizer to reverse chemoresistance of cisplatin-resistant cervical cancer to cisplatin through repressing NRF2 expression partly associated with PI3K/AKT blockage.
|
31056260 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current research elucidated that MFI2 promoted cell proliferation, cell metastasis and inhibited cell apoptosis in cervical cancer by regulating the PI3K/AKT signaling pathway.
|
31210294 |
2019 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western blotting was utilized to validate whether NEAT1 promotes cervical cancer progression through activating PI3K-Akt signaling pathway.
|
30127216 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway.
|
29175387 |
2018 |
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.
|
29423104 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we aimed to explore whether miR-486-5p is a regulator in the development of cervical cancer through the PI3K/Akt pathway by targeting PTEN.
|
29316891 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibulin-3 promoted cervical cancer cell invasive capabilities by eliciting EMT and activating the PI3K-Akt-mTOR signal transduction pathway.
|
30006571 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
microRNA-383 suppresses the PI3K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via down-regulating PARP2.
|
29236322 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that SKA3 overexpression contributes to CC cell growth and migration by promoting cell cycle progression and activating the PI3K-Akt signaling pathway, which may provide potential novel therapeutic targets for CC treatment.
|
30459531 |
2018 |
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings provide evidence that the PI3K E542K and E545K/β-catenin/SIRT3 signaling axis regulates glucose metabolism and proliferation in cervical cancers with PIK3CA mutations, suggesting therapeutic targets in the treatment of cervical cancers.
|
30547809 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-338 modulates proliferation and autophagy by PI3K/AKT/mTOR signaling pathway in cervical cancer.
|
29898430 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA‑433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling by targeting FAK.
|
30272334 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer.
|
29777148 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
|
29328485 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tobacco Exposure Enhances Human Papillomavirus 16 Oncogene Expression via EGFR/PI3K/Akt/c-Jun Signaling Pathway in Cervical Cancer Cells.
|
30619121 |
2018 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study suggests that R7 is a promising chemotherapeutic agent for the treatment of cervical cancer and other PI3K/PTEN/Akt/mTOR signaling-associated tumors.
|
29312623 |
2017 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy.
|
28475243 |
2017 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant activation of the phosphoinositide-3-kinase (PI3K) pathway frequently occurs in solid tumors, including cervical cancer.
|
28036259 |
2017 |
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventy percent of patients with endometrial cancer and more than 50% of patients with breast, prostate, anal, hepatocellular, colorectal, and cervical cancer exhibited alterations in at least 1 PI3K pathway gene and/or gene product.
|
27388585 |
2016 |
cervical cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor-Suppressor Gene NBPF1 Inhibits Invasion and PI3K/mTOR Signaling in Cervical Cancer Cells.
|
26802646 |
2016 |